CA2205064A1 - Compositions stables de proteines/acide diethylenetriamine pentacetique a liaison n-terminale et procedes associes - Google Patents

Compositions stables de proteines/acide diethylenetriamine pentacetique a liaison n-terminale et procedes associes

Info

Publication number
CA2205064A1
CA2205064A1 CA 2205064 CA2205064A CA2205064A1 CA 2205064 A1 CA2205064 A1 CA 2205064A1 CA 2205064 CA2205064 CA 2205064 CA 2205064 A CA2205064 A CA 2205064A CA 2205064 A1 CA2205064 A1 CA 2205064A1
Authority
CA
Canada
Prior art keywords
csf
dtpa
protein
rhg
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2205064
Other languages
English (en)
Inventor
Lloyd D. Ralph
David C. Litzinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/US1995/015072 external-priority patent/WO1996015816A2/fr
Publication of CA2205064A1 publication Critical patent/CA2205064A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des compositions de protéines/d'acide diéthylènetriamine pentacétique (DTPA) dans lesquelles l'agent chélateur DTPA a été conjugué de manière dirigée à l'extrémité azotée de la protéine, permettant ainsi la formation d'un produit homogène et bien défini, capable de former des complexes avec une diversité de radionucléides métalliques. Les compositions selon cette invention peuvent être produites en grande quantité et conserver une bioactivité in vivo totale, avec ou sans les radionucléides métalliques chélatés. Elles peuvent convenir au diagnostic, à l'imagerie et/ou au traitement de la leucémie et des maladies associées.
CA 2205064 1994-11-17 1995-11-17 Compositions stables de proteines/acide diethylenetriamine pentacetique a liaison n-terminale et procedes associes Abandoned CA2205064A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34248194A 1994-11-17 1994-11-17
US08/342,481 1994-11-17
PCT/US1995/015072 WO1996015816A2 (fr) 1994-11-17 1995-11-17 Compositions stables de proteines/acide diethylenetriamine pentacetique a liaison n-terminale et procedes associes

Publications (1)

Publication Number Publication Date
CA2205064A1 true CA2205064A1 (fr) 1996-05-30

Family

ID=29405873

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2205064 Abandoned CA2205064A1 (fr) 1994-11-17 1995-11-17 Compositions stables de proteines/acide diethylenetriamine pentacetique a liaison n-terminale et procedes associes

Country Status (1)

Country Link
CA (1) CA2205064A1 (fr)

Similar Documents

Publication Publication Date Title
US5225180A (en) Technetium-99m labeled somatostatin-derived peptides for imaging
EP3470418B1 (fr) Anticorps marqué par radioisotope spécifique d'un site utilisant un peptide liant une igg
DE69434086T2 (de) Herstellung und Verwendung von Immunkonjugaten die eine VL-Kette enthalten welche am Asn in Position 18 glykosyliert ist
FI81263C (fi) Foerfarande foer maerkning av en maolsoekande biologiskt aktiv molekyl och metalltionein.
US5277892A (en) In vivo lymphocyte tagging
AU649079B2 (en) Modified antibodies with controlled clearance time
KR100235137B1 (ko) 모노아민, 다아민, 티올-함유 금속 킬레이트제
JP2727074B2 (ja) 像形成組成物及び標的用ポリペプチド
Kobayashi et al. L-lysine effectively blocks renal uptake of 125I-or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment
Chianelli et al. The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases
EP3783016A1 (fr) Anticorps modifié et anticorps marqué par un métal radioactif
JPH08509001A (ja) 炎症をイメージングするためのテクネチウム−９９ｍ標識ペプチド
US5728369A (en) Radioactive phosphorus labeling of proteins for targeted radiotherapy
KR100385340B1 (ko) 금속킬레이트형성펩티드및그의용도
US20020164302A1 (en) Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
AU709012B2 (en) Stable N-terminally linked DTPA:protein compositions and methods
JP4279781B2 (ja) 白血球結合性化合物およびその標識化合物を有効成分とする医薬組成物
Verbeke et al. Technetium-99m mercaptoalbumin as a potential substitute for technetium-99m labelled red blood cells
US6551574B2 (en) Tuftsin metallopeptide analogs and uses thereof
MXPA97003549A (en) Stable dietilentriaminopentaacetic acid, jointed by the end of n: compositions of protein and met
CA2205064A1 (fr) Compositions stables de proteines/acide diethylenetriamine pentacetique a liaison n-terminale et procedes associes
WO1993009816A1 (fr) Procede de diagnostic et de traitement du cancer
US5643549A (en) Leukostimulatory agent for in vivo leukocyte tagging
EP0700930B1 (fr) Peptides à affinité pour des tumeurs et composés radioactifs diagnostiques et thérapeutiques les contenant
Ralph et al. Site-specific conjugation of diethylenetriaminepentaacetic acid to recombinant human granulocyte-colony-stimulating factor: preservation of protein structure and function

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead